Bertilimumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | CCL11 (eotaxin-1) |
| Identifiers | |
| CAS Number |
375348-49-5  |
| ATC code | None |
| ChemSpider | none |
 (what is this?) (verify) | |
Bertilimumab is a human monoclonal antibody that binds to eotaxin-1, an important regulator of overall eosinophil function.
It was discovered by Cambridge Antibody Technology using their phage display technology.[1] Named CAT-213 during early discovery and development by CAT, it was to be used to treat severe allergic disorders.[2]
In January 2007, CAT licensed the drug for treatment of allergy disorders to iCo Therapeutics Inc.[3] iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications - a so-called 'search and development company'.[4]
iCo Therapeutics Inc. renamed the drug from CAT-213 to iCo-008 and, at that stage, planned to initiate a Phase II clinical trial in patients with vernal keratoconjunctivitis.[5]
In March 2008, iCo announced iCo-008 had been in 126 patients in Phase I and II clinical trials. The drug substance had been manufactured by Lonza, in its cGMP facilities in Slough, UK. Subsequently iCo moved the drug substance to a fill-finish site for the final stage of manufacturing. iCo reported that the iCo-008 drug product was within specifications and contained a high antibody yield.[6]
In June 2011, IMMUNE Pharmaceuticals (NASDAQ: IMNP) [7] (Herzliya, Israel) in-licensed Bertilimumab from iCo for non-ophthalmic indications. [8] IMMUNE is initiating Phase II clinical trials of Bertilimumab in inflammatory bowel disease (ulcerative colitis & Crohn's disease) in 2015 and 2016. Other indications planned for Bertilimumab development include severe asthma and liver disease (NASH).
References
- ↑ http://jpet.aspetjournals.org/cgi/content/abstract/319/3/1395
- ↑ "Bertilimumab Cambridge Antibody Technology Group" 5 (11). November 2004: 1213–8. PMID 15573873.
- ↑ http://www.icotherapeutics.com/site/investor-relations/cambridge_antibody_tech_licenses_monoclonal_antibody_treatment_allergy/
- ↑ http://www.icotherapeutics.com/site/corporate_overview/overview/
- ↑ http://www.icotherapeutics.com/site/pipeline/ico008/
- ↑ http://www.icotherapeutics.com/site/investor-relations/ico_therapeutics_provides_ico_008_phase_ii_clinical_update/
- ↑ http://immunepharmaceuticals.com/
- ↑ http://immunepharmaceuticals.com/index.php?option=com_content&view=article&id=32&Itemid=20
| ||||||||||||||||||||||||||||||||||||||||||||||||||||